Phase 1 Trial Evaluates DS-6000a in RCC and Ovarian Cancer

Partners | <b>Tennessee Oncology</b>

Erika P. Hamilton, MD, discusses the background of a phase 1 trial of DS-6000a in patients with advanced renal cell carcinoma and ovarian cancer.

Erika P. Hamilton, MD, lead investigator and director of the Breast and Gynecologic Cancer Research Program at the Sarah Cannon Research Institute/Tennessee Oncology, discusses the background of a phase 1 trial of DS-6000a in patients with advanced renal cell carcinoma (RCC) and ovarian cancer (NCT04707248).

This 2-part, multicenter, first-in-human, phase 1 study will evaluate DS-6000a given as a single agent once every 21 days in patients with platinum resistant ovarian cancer or RCC.

In the dose escalation phase of the trial, participants with ovarian cancer and RCC will be enrolled to assess the safety and tolerability of DS-6000a and to determine the maximum tolerated dose for the expansion portion. In the dose expansion portion of the trial, investigators will assess the clinical activity of DS-6000a.

Transcription:

0:08| [DS-6000a] is an antibody-drug conjugate that is targeting something called cadherin 6 or CDH6. It is the same platform as drugs that you might be more familiar with like fam-trastuzumab deruxtecan-nxki [Enhertu] or datopotamab deruxtecan [Dato-DXd]. Essentially, the drug to antibody ratio is 8 and it's given intravenously every 3 weeks like some of its cousins.

0:31 | The patients that were enrolled onto this trial had either renal cell carcinoma or platinum resistant ovarian carcinoma. About a third of the patients on the trial had renal cell and about two thirds that had ovarian cancer. Now for the patients that had renal cell, the median number of priors was 2, whereas the patients that had ovarian cancer had a median number of priors of 4. A lot of patients remain on this drug. Upwards of almost 60% of the patients that we reported data on are still on drugs, still doing well, without their cancer growing.